Currently, there are 199.78M common shares owned by the public and among those 134.40M shares have been available to trade.
The company’s stock has a 5-day price change of 45.39% and -1.91% over the past three months. ATAI shares are trading 54.14% year to date (YTD), with the 12-month market performance up to 10.22% higher. It has a 12-month low price of $1.03 and touched a high of $2.57 over the same period. ATAI has an average intraday trading volume of 1.82 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 35.18%, 41.82%, and 42.34% respectively.
Institutional ownership of ATAI Life Sciences N.V (NASDAQ: ATAI) shares accounts for 9.82% of the company’s 199.78M shares outstanding.
It has a market capitalization of $410.69M and a beta (3y monthly) value of 1.33. The earnings-per-share (ttm) stands at -$0.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.00% over the week and 8.21% over the month.
Earnings per share for the fiscal year are expected to increase by 39.13%, and -10.62% over the next financial year. EPS should grow at an annualized rate of 29.20% over the next five years, compared to 18.62% over the past 5-year period.
Looking at the support for the ATAI, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 18, 2024, with the firm’s price target at $15-$10. Maxim Group coverage for the ATAI Life Sciences N.V (ATAI) stock in a research note released on April 03, 2024 offered a Buy rating with a price target of $6. Loop Capital was of a view on November 01, 2022 that the stock is Buy, while Maxim Group gave the stock Buy rating on November 30, 2021, issuing a price target of $25. ROTH Capital on their part issued Buy rating on November 11, 2021.
